Disha Dadke

422 total citations
8 papers, 228 citations indexed

About

Disha Dadke is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Disha Dadke has authored 8 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in Disha Dadke's work include Radiopharmaceutical Chemistry and Applications (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and Ubiquitin and proteasome pathways (2 papers). Disha Dadke is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and Ubiquitin and proteasome pathways (2 papers). Disha Dadke collaborates with scholars based in United States, India and Slovakia. Disha Dadke's co-authors include Erica A. Golemis, Mahendra Singh, Benjamin H. Fryer, Jeffrey Field, Émmanuelle Nicolas, Michael Jarnik, Elena N. Pugacheva, Sinoula Apostolou, Adrian A. Canutescu and Ilya G. Serebriiskii and has published in prestigious journals such as Oncogene, Annals of Oncology and Molecular Biology of the Cell.

In The Last Decade

Disha Dadke

7 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Disha Dadke United States 6 155 64 61 42 31 8 228
Takao Morinaga Japan 9 151 1.0× 70 1.1× 62 1.0× 15 0.4× 29 0.9× 23 229
Tessa Humphries‐Bickley Puerto Rico 5 253 1.6× 79 1.2× 127 2.1× 24 0.6× 39 1.3× 6 359
Galina Shagieva Russia 10 126 0.8× 49 0.8× 98 1.6× 26 0.6× 37 1.2× 16 253
Rolf‐Peter Scholz Germany 6 243 1.6× 59 0.9× 84 1.4× 22 0.5× 38 1.2× 6 279
Ryan J. Ice United States 10 179 1.2× 98 1.5× 91 1.5× 31 0.7× 63 2.0× 14 293
Johanna I. Englund Finland 7 99 0.6× 48 0.8× 37 0.6× 15 0.4× 33 1.1× 12 188
Moon-Chang Choi South Korea 9 379 2.4× 90 1.4× 58 1.0× 19 0.5× 54 1.7× 11 456
Lorena A. Puto United States 6 246 1.6× 87 1.4× 40 0.7× 15 0.4× 59 1.9× 6 320
Tianmu Wen United States 8 166 1.1× 54 0.8× 91 1.5× 10 0.2× 26 0.8× 13 260
Oleksandr Voytyuk Sweden 7 217 1.4× 139 2.2× 67 1.1× 14 0.3× 35 1.1× 7 319

Countries citing papers authored by Disha Dadke

Since Specialization
Citations

This map shows the geographic impact of Disha Dadke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Disha Dadke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Disha Dadke more than expected).

Fields of papers citing papers by Disha Dadke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Disha Dadke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Disha Dadke. The network helps show where Disha Dadke may publish in the future.

Co-authorship network of co-authors of Disha Dadke

This figure shows the co-authorship network connecting the top 25 collaborators of Disha Dadke. A scholar is included among the top collaborators of Disha Dadke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Disha Dadke. Disha Dadke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Nagarkar, Rajnish, et al.. (2024). Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical Drug Investigation. 44(7). 513–525.
2.
Kothari, Ramesh K., et al.. (2023). 67P Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study. Annals of Oncology. 34. S1491–S1491. 1 indexed citations
3.
Singh, Mahendra, Disha Dadke, Émmanuelle Nicolas, et al.. (2008). A Novel Cas Family Member, HEPL, Regulates FAK and Cell Spreading. Molecular Biology of the Cell. 19(4). 1627–1636. 56 indexed citations
4.
Singh, Mahendra, et al.. (2007). HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins. Oncogene. 26(33). 4825–4832. 34 indexed citations
5.
Dadke, Disha, Michael Jarnik, Elena N. Pugacheva, Mahendra Singh, & Erica A. Golemis. (2006). Deregulation of HEF1 Impairs M-Phase Progression by Disrupting the RhoA Activation Cycle. Molecular Biology of the Cell. 17(3). 1204–1217. 52 indexed citations
6.
Dadke, Disha, Benjamin H. Fryer, Erica A. Golemis, & Jeffrey Field. (2003). Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation.. PubMed. 63(24). 8837–47. 56 indexed citations
7.
Dadke, Disha, et al.. (2002). The detection of HBV antigens and HBx‐transcripts in an Indian fibrolamellar carcinoma patient: a case study. Liver International. 22(1). 87–91. 11 indexed citations
8.
Golemis, Erica A., Kenneth D. Tew, & Disha Dadke. (2002). Protein Interaction-Targeted Drug Discovery: Evaluating Critical Issues. BioTechniques. 32(3). 636–647. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026